The Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) has voted to recommend that pediatric patients (2 to 18 years old) who have not previously received hepatitis A vaccine be routinely vaccinated at any age. Currently, the CDC recommends routine hepatitis A vaccination for children 12 to 23 months of…
Direct-acting antiviral (DAA) exposure may not be associated with higher rates of any serious adverse events when used for hepatitis C virus (HCV) treatment, according to a study published in JAMA Network Open. At this time, there are approximately 2.4 million individuals living in the United States who are infected with HCV. Further, 28% of…
Investigators sought to determine the risk for Parkinson disease development in patients with hepatitis C virus who received antiviral treatment and in patients who did not receive this treatment.
The novel method of lateral flow immunoassay may be a cost-effective way to identify patients with chronic hepatitis B virus infection.
Fibronectin may be a potential marker for hepatitis B surface antigen seroclearance.
Advantage of interferon-based antiviral therapy reached statistical significance at five-year follow-up
In a large cohort of patients with HCV, the use of DAA was associated with significantly lower incidence and risk for subsequent diabetes.
Hepatitis B e antigen prevalence and other hepatitis B virus markers decline with age and differ by race with HBeAg persisting longer among Asian people.
The FDA has approved Mavyret for the treatment of all 6 genotypes of hepatitis C virus in children 12 to 17 years old or weighing at least 45kg.
In onsite HCV care delivered to PWID in opioid agonist therapy programs, a greater adherence was associated with directly observed therapy when compared with self-administered individual treatment.
An 8- or 12-week regimen of glecaprevir and pibrentasvir is efficacious and safe in patients with HCV infection after liver transplantation.
Treatment with DAAs before liver transplantation is associated with improved outcome and appears to be safe in patients with decompensated hepatitis C-related cirrhosis.
There was no significant effect of maternal tenofovir use for the prevention of mother-to-child transmission of HBV on bone mineral density in either the mother or child 1 year after delivery.
Patients with TB and HBV co-infection should be given antiviral treatment for HBV when anti-TB therapy is initiated.
The impact of direct-acting antiviral therapy was investigated in a large cohort of patients in complete remission following treatment of hepatitis C-related HCC.
Occult hepatitis B virus infection was detected in 50% of patients with chronic hepatitis C with CHC-related hepatocellular carcinoma.
Findings suggest that states should consider revising their HCV treatment policies to include all individuals infected with HCV to achieve significant patient- and population-level benefits.
The AGA present an updated summary of best practice advice for surveillance of hepatocellular cancer and DAA therapy timing.
Data suggests that prevention strategies and frequent testing with HCV-RNA should be applied after sustained virologic response in MSM who engage in high-risk practices.
Report describes progress made to achieve hepatitis B control in the Western Pacific Region and the steps taken to eliminate mother-to-child transmission of hepatitis B virus during 2005 to 2017.